| abstract |
DGAT-1 inhibitors of the compound of formula (I) are described, their pharmaceutically acceptable salts and prodrugs, as well as pharmaceutical compositions containing them, methods for their preparation and their use in the treatment of, for example, obesity, where, for example, ring A is optionally substituted 2 6-pyrazindiyl; X represents = O; ring B is a possibly substituted 1,4-phenylene; Y is a direct bond or —O—; Y is - (CH) -, where r is 2 or 3; n is 0, or n is 1 when Y is a direct bond between ring B and ring C, and when ring B is 1,4-phenylene and ring C is (4-6C) cycloalkane; ring C is an optionally substituted (4-6C) cycloalkane, (7-10C) bicycloalkane, (8-12C) tricycloalkane, phenylene or pyridinediyl; L is a direct bond or —O—; p is 0, 1 or 2, and when p is 1, or each of 2 R and R is independently hydrogen or (1-4C) alkyl; Z represents a carboxy group or a mimetic thereof, or a bioisostere. |